A. Ulankyzy
Research Subjects
A. Ulankyzy has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Gulnur Nakhanova
ТОО Научно-исследовательский институт проблем биологической безопасности, АО Национальный холдинг QazBioPharm, Жамбылская область, Казахстан
3 shared publications - Sabina U. Moldagulova
«Research Institute for Biological Safety Problems» Ministry of Health of the Republic of Kazakhstan
3 shared publications - A. S. Zhakypbek
LLP «Research Institute for Biological Safety Problems», National holding «QazBioPharm
2 shared publications - Alisher D. Omurtay
Research Institute for Biological Safety Problems
2 shared publications - Kamshat Abithanovna Shorayeva
Research Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan
2 shared publications - Kuanysh Jekebekov
Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
2 shared publications
Latest Publications
- 6 October 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 3,p. 285-283
DEVELOPMENT AND STANDARDIZATION STRATEGY FOR QUALITY CONTROL OF A RECOMBINANT CAPRIPOXVIRUS-VECTORED VACCINE AGAINST BRUCELLOSIS
This work presents the development and implementation of a quality control and standardization strategy for a recombinant capripoxvirus-vectored vaccine against brucellosis. We conducted a comprehensive analysis of World Health Organization guidelines, the State Pharmacopoeia of the Republic of Kazakhstan, and regulatory documents governing quality control of biological medicinal products. Based on this analysis, we established a comprehensive panel of quality parameters encompassing physicochemical, molecular-genetic, biological, and microbiological characteristics of the vaccine, as well as assessment of residual process-related impurities. Using the developed strategy, we evaluated three pilot batches of the recombinant capripoxvirus-vectored brucellosis vaccine. The results demonstrated that all pilot batches met the established quality and safety requirements. The developed quality control and standardization strategy provides a foundation for further refinement of the evaluation system for recombinant vector-based brucellosis vaccines and for the preparation of regulatory documentation to support their clinical application.
- 6 October 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 3,p. 285-283
DEVELOPMENT AND STANDARDIZATION STRATEGY FOR QUALITY CONTROL OF A RECOMBINANT CAPRIPOXVIRUS-VECTORED VACCINE AGAINST BRUCELLOSIS
This work presents the development and implementation of a quality control and standardization strategy for a recombinant capripoxvirus-vectored vaccine against brucellosis. We conducted a comprehensive analysis of World Health Organization guidelines, the State Pharmacopoeia of the Republic of Kazakhstan, and regulatory documents governing quality control of biological medicinal products. Based on this analysis, we established a comprehensive panel of quality parameters encompassing physicochemical, molecular-genetic, biological, and microbiological characteristics of the vaccine, as well as assessment of residual process-related impurities. Using the developed strategy, we evaluated three pilot batches of the recombinant capripoxvirus-vectored brucellosis vaccine. The results demonstrated that all pilot batches met the established quality and safety requirements. The developed quality control and standardization strategy provides a foundation for further refinement of the evaluation system for recombinant vector-based brucellosis vaccines and for the preparation of regulatory documentation to support their clinical application.
- Open Access
- 20 September 2026
- Published by al-Farabi Kazakh National University in Experimental Biology
- Vol. 108 (3) , 133-144
ПОДТВЕРЖДЕНИЕ ПОДЛИННОСТИ РЕКОМБИНАНТНЫХ ВИРУСОВ ГРИППА МЕТОДОМ ПЦР - ИДЕНТИФИКАЦИЯ ГЕНЕТИЧЕСКИХ ВСТАВОК, КОДИРУЮЩИХ РЕКОМБИНАНТНЫЕ БЕЛКИ BRUCELLA SPP.
The development of viral vector vaccines against brucellosis requires strict control of the authenticity of recombinant strains used as vaccine candidates. One of the key stages in the molecular characterization of such strains is confirmation of the presence of heterologous genetic inserts encoding Brucella antigens. The aim of this study was to assess the authenticity of recombinant influenza strains by detecting brucellosis-related genetic inserts using reverse transcription polymerase chain reaction (RT-PCR). The study objects were recombinant influenza virus strains Flu-NS1-80-Omp16, Flu-NS1-80-L7/L12, Flu-NS1-80-Omp19, and Flu-NS1-80-Cu-Zn SOD, containing genes encoding immunodominant Brucella proteins. Analytical sensitivity was evaluated using serial tenfold dilutions of a positive control with a known RNA concentration. The specificity of the method was confirmed by the presence of amplicons of the expected size, approximately 1250–1300 bp for recombinant constructs and approximately 890 bp for the control virus, as well as by the absence of nonspecific amplification in negative controls. During the analysis of recombinant strains Flu-NS1-80-OMP16, Flu-NS1-80-OMP19, Flu-NS1-80-SOD, and Flu-NS1-80-L7/L12, target fragments were detected in all samples, indicating successful integration of Brucella spp. inserts into the viral genome. Reproducibility assessment showed 100% concordance of results in 10 independent replicates for all tested samples. The positive and negative controls demonstrated the expected results, confirming the correct performance of the reaction and the absence of contamination. The obtained results confirm the authenticity of the recombinant influenza strains and the presence of brucellosis-related genetic inserts in their genome, indicating the correctness of the viral vector constructs and their potential for further use in the development of vaccine preparations against brucellosis.
- 20 September 2026
- Published by al-Farabi Kazakh National University in Experimental Biology
- Vol. 108 (3) , 133-144
Open AccessПОДТВЕРЖДЕНИЕ ПОДЛИННОСТИ РЕКОМБИНАНТНЫХ ВИРУСОВ ГРИППА МЕТОДОМ ПЦР - ИДЕНТИФИКАЦИЯ ГЕНЕТИЧЕСКИХ ВСТАВОК, КОДИРУЮЩИХ РЕКОМБИНАНТНЫЕ БЕЛКИ BRUCELLA SPP.
The development of viral vector vaccines against brucellosis requires strict control of the authenticity of recombinant strains used as vaccine candidates. One of the key stages in the molecular characterization of such strains is confirmation of the presence of heterologous genetic inserts encoding Brucella antigens. The aim of this study was to assess the authenticity of recombinant influenza strains by detecting brucellosis-related genetic inserts using reverse transcription polymerase chain reaction (RT-PCR). The study objects were recombinant influenza virus strains Flu-NS1-80-Omp16, Flu-NS1-80-L7/L12, Flu-NS1-80-Omp19, and Flu-NS1-80-Cu-Zn SOD, containing genes encoding immunodominant Brucella proteins. Analytical sensitivity was evaluated using serial tenfold dilutions of a positive control with a known RNA concentration. The specificity of the method was confirmed by the presence of amplicons of the expected size, approximately 1250–1300 bp for recombinant constructs and approximately 890 bp for the control virus, as well as by the absence of nonspecific amplification in negative controls. During the analysis of recombinant strains Flu-NS1-80-OMP16, Flu-NS1-80-OMP19, Flu-NS1-80-SOD, and Flu-NS1-80-L7/L12, target fragments were detected in all samples, indicating successful integration of Brucella spp. inserts into the viral genome. Reproducibility assessment showed 100% concordance of results in 10 independent replicates for all tested samples. The positive and negative controls demonstrated the expected results, confirming the correct performance of the reaction and the absence of contamination. The obtained results confirm the authenticity of the recombinant influenza strains and the presence of brucellosis-related genetic inserts in their genome, indicating the correctness of the viral vector constructs and their potential for further use in the development of vaccine preparations against brucellosis.
- Open Access
- 10 April 2026
- Published by Research Institute for Biological Safety Problems in Biosafety and Biotechnology
- No. 24,p. 44-54
QUALITY CONTROL OF EXPERIMENTAL BATCHES OF THE PREPARATION AGAINST ESKAPE PATHOGENS
The global increase in antibiotic resistance, particularly among pathogens of the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae), highlights the urgent need for alternative antimicrobial approaches. One promising strategy is phage therapy, which involves the use of bacteriophages capable of specifically lysing bacterial cells. The aim of this study was to evaluate the quality parameters of experimental batches of the preparation “Bacteriophage against ESKAPE pathogens,” developed at the Research Institute for Biological Safety Problems LLP, Republic of Kazakhstan. Three experimental batches of the preparation (No. 0011224, No. 0021224, No. 0031224) were examined for appearance, extractable volume, hydrogen ion concentration (pH), sterility, and specific activity against ESKAPE test cultures in accordance with SK-ESKAPE-PR-23 requirements, the State Pharmacopoeia of the Republic of Kazakhstan, and regulatory guidelines of the Eurasian Economic Union for biological medicinal products. The results demonstrated that all batches met the established quality requirements, showing stable physicochemical properties, confirmed sterility, and high specific activity maintained at dilutions up to 10⁻⁷–10⁻¹⁰. These findings confirm the stability, quality, and biological efficacy of the investigated bacteriophage preparation and support its potential for further development and application in the prevention and treatment of infections caused by antibiotic-resistant ESKAPE pathogens.
- 10 April 2026
- Published by Research Institute for Biological Safety Problems in Biosafety and Biotechnology
- No. 24,p. 44-54
Open AccessQUALITY CONTROL OF EXPERIMENTAL BATCHES OF THE PREPARATION AGAINST ESKAPE PATHOGENS
The global increase in antibiotic resistance, particularly among pathogens of the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae), highlights the urgent need for alternative antimicrobial approaches. One promising strategy is phage therapy, which involves the use of bacteriophages capable of specifically lysing bacterial cells. The aim of this study was to evaluate the quality parameters of experimental batches of the preparation “Bacteriophage against ESKAPE pathogens,” developed at the Research Institute for Biological Safety Problems LLP, Republic of Kazakhstan. Three experimental batches of the preparation (No. 0011224, No. 0021224, No. 0031224) were examined for appearance, extractable volume, hydrogen ion concentration (pH), sterility, and specific activity against ESKAPE test cultures in accordance with SK-ESKAPE-PR-23 requirements, the State Pharmacopoeia of the Republic of Kazakhstan, and regulatory guidelines of the Eurasian Economic Union for biological medicinal products. The results demonstrated that all batches met the established quality requirements, showing stable physicochemical properties, confirmed sterility, and high specific activity maintained at dilutions up to 10⁻⁷–10⁻¹⁰. These findings confirm the stability, quality, and biological efficacy of the investigated bacteriophage preparation and support its potential for further development and application in the prevention and treatment of infections caused by antibiotic-resistant ESKAPE pathogens.